• Home
  • Huntington’s disease
  • important
  • Articles
    • Scientific Articles Free
    • Italian articles
  • ARTICLES SCIENTIFIC
  • Link
Search
  • Contact
  • Sitemap
  • Donate
  • Newsletters
  • www.aichroma.com
  • Italian | Español | French

Huntington's Disease News

  • Home
  • Huntington’s disease
  • important
    • Discovery shows promise for treating Huntington’s Disease

      Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s…

      uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s…

      Huntington’s disease-causing DNA repeat mutations reversed in the lab

      uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease…

  • Articles
    • Scientific Articles Free
    • Italian articles
  • ARTICLES SCIENTIFIC
  • Link

Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial...

Ott 27, 2020

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Ott 23, 2020

Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation...

Ott 21, 2020

uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical...

Ott 14, 2020

Updates from the EHDN Plenary Meeting 2020

Ott 7, 2020

When genes are unstable: targeting somatic instability in HD

Ago 27, 2020

World first study reveals altered gut bacteria in Huntington’s Disease which...

Ago 6, 2020

Discovery shows promise for treating Huntington’s Disease

Ago 6, 2020

Neural vulnerability in Huntington’s disease tied to release of mitochondrial RNA

Lug 22, 2020

Study reveals intricate details about Huntington’s disease protein

Lug 20, 2020
123...127Page 2 of 127
ABOUT US
AICH - ROMA ONLUS: VIA NOMENTANA 56, 00161 ROMA TEL/FAX 06.44242033 c/c postale n. 35453000 C.F. 96152570584
FOLLOW US
  • Discliminair
  • Contact
  • Donate
  • Sitemap
© newshd.net
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Discliminair
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessario
Sempre attivato

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non necessario

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.